REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

PHASE3CompletedINTERVENTIONAL
Enrollment

203

Participants

Timeline

Start Date

February 28, 2019

Primary Completion Date

August 23, 2022

Study Completion Date

September 15, 2022

Conditions
Cervical DysplasiaCervical High Grade Squamous Intraepithelial LesionHSIL
Interventions
BIOLOGICAL

VGX-3100

1 milliliter (mL) VGX-3100 injected IM.

BIOLOGICAL

Matched Placebo

1 mL of matched Placebo injected IM.

DEVICE

CELLECTRA™-5PSP

CELLECTRA™-5PSP used for EP following IM injection of VGX 3100.

Trial Locations (53)

7925

University of Cape Town, Cape Town

10032

Columbia University Medical Center, New York

10119

East Tallinn Central Hospital Womens Clinic, Tallinn

10583

Montefiore Medical Center, The Bronx

11777

Suffolk Obstetrics and Gynecology, Port Jefferson

15478

Frontier Clinical Research-Smithfield, Smithfield

19713

Christiana Care Health System, Newark

21740

Unified Women's Clinical Research - Hagerstown, Hagerstown

23456

Group For Women - Tidewater Clinical Research Inc., Virginia Beach

27103

Lyndhurst Clinical Research, Winston-Salem

27408

Unified Women's Clinical Research - Greensboro, Greensboro

28009

Hospital General Universitario Gregorio Maranon, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

28557

Unified Women's Clinical Research - Morehead City, Morehead City

29572

Venus Gynecology, LLC, Myrtle Beach

30912

Augusta University, Augusta

33027

Salom and Tangir LLC, Miramar

33351

Precision Clinical Research, LLC, Sunrise

33461

Altus Research, Lake Worth

38119

Women's Physician Group Suite 203, Memphis

43213

ClinOhio Research Services, Columbus

45014

Obstetrics & Gynecology Associates, Inc., Fairfield

46010

Hospital Clinico Universitario de Valencia, Valencia

46026

Hospital Universitari i Politecnic La Fe de Valencia, Valencia

48604

Saginaw Valley Medical Research Group LLC, Saginaw

51014

Tartu University Hospital, Tartu

60523

Affinity Clinical Research Institute, Oak Brook

68701

Meridian Clinical Research Norfolk, Norfolk

70072

Praetorian Pharmaceutical Research, LLC, Marrero

77479

Storks Research, Sugar Land

85712

Visions Clinical Research- Tucson, Tucson

06810

Nuvance Health, Danbury

02118

Boston Medical Center, Boston

07103

New Jersey Medical School, Newark

S2000PBB

Instituto de Ginecología, Rosario

C1181ACH

Hospital Italiano de Buenos Aires, Buenos Aires

B1704ETD

DIM Clinica Privada, Ramos Mejía

40420-000

Associação Obras Sociais Irmã Dulce Hospital Santo Antônio, Salvador

74605-050

Hospital das Clinicas de Goiânia, Goiânia

80530-010

Hospital Erasto Gaertner, Curitiba

17210-120

Hospital Amaral Carvalho, Jaú

14048-900

Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP, Ribeirão Preto

EE-80010

Pärnu Hospital, Pärnu

FI-00290

HUS Naistentaudit ja synnytykset, Helsinki

FI-70210

Northern Savo Hospital District Muncipal Federation, Kuopio

LT-01117

Vilnius District Central Outpatient Clinic, Vilnius

LT-08661

Vilnius University Hospital Santaros Klinikos, Vilnius

20-880

Niepubliczny Zakład Opieki Zdrowotnej Profimed, Lublin

Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie, Lublin

40-611

Centrum Medyczne Angelius Provita, Śląskie

00935

Puerto Rico Translational Research Center (PRTRC), Rio Piedras

0157

Lynette Reynders Private Practice, Centurion

08907

Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat

Sponsors
All Listed Sponsors
lead

Inovio Pharmaceuticals

INDUSTRY

NCT03721978 - REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) | Biotech Hunter | Biotech Hunter